
CRISPR’s New Dawn: The Billion-Dollar Cure Rocking the Medical World
CRISPR Therapeutics’ Casgevy receives FDA approval as a groundbreaking treatment for sickle cell disease, highlighting the potential of genetic therapy. The $2.2 million cost of treatment sparks concerns over accessibility and health disparities. Attention shifts to CTX112, a new treatment for blood